Abstract. Protein/nucleic acid deglycase DJ-1 (DJ-1) is a 20-kDa conserved protein, which belongs to the DJ-1/ThiJ/Pfp I protein superfamily. Immunohistochemistry was performed to investigate the expression of DJ-1 in a colorectal cancer (CRC) tissue microarray containing tumor and corresponding adjacent normal tissues. In the present study, DJ-1 expression was significantly upregulated in CRC cells and tissues, compared with that in normal colon cells and adjacent normal tissues, respectively. In addition, patients with high DJ-1 expression levels had a worse overall survival (OS) compared with patients with low expression levels. Multivariate Cox regression analysis revealed that high DJ-1 expression levels was an independent prognostic factor for patients with CRC. Moreover, DJ-1 was able to regulate the PI3K/Akt/p27/cyclin E and PI3K/Akt/mTOR signaling pathways to promote CRC cell growth and metastasis in vitro and in vivo. In addition, DJ-1 regulated the NF-κB/Snail signaling pathway to induce CRC cell epithelial-mesenchymal transition to promote migration and invasion. Notably, patients receiving LFP treatment (oxaliplatin, 5-FU and tetrahydrofolate) had an increased OS compared with patients who underwent only surgery and low DJ-1 expression levels. The findings from the present study suggest that DJ-1 may serve as a promising prognostic marker and predicts chemotherapy efficacy in patients with CRC.

Introduction

Colorectal cancer (CRC) is the second most commonly diagnosed gastrointestinal malignant neoplasm, and one of the leading causes of cancer-associated mortality all over the world in 2015 (1). There were ~1.4 million new cases and 0.7 million deaths worldwide in 2012 (2). The recurrence rate is higher than 11 and 40-50% in postoperative patients with stage II and III CRC, respectively (3). The high recurrence rate of CRC is a major contributor to poor prognosis, and poor prognosis in patients with CRC is associated with tumor invasion and metastasis (4,5). The development of metastasis is complex, and includes proliferation, angiogenesis, invasion, detachment, migration, adhesion and extravasation into target organs (4). Research investigating the mechanism into the origin and development of CRC has identified a high number of biomarkers, as well as identifying signaling pathways that are vital for tumorigenesis and progression of CRC (5). However, only a few of the identified biomarkers have clinicopathological significance in CRC. Therefore, it is important to identify additional master genes that are associated with the progression and metastasis of CRC, which may provide more reliable molecular targets for therapy and improve the prognosis of CRC patients.

Protein/nucleic acid deglycase DJ-1 (DJ-1) is a 20-kDa conserved protein, which belongs to the DJ-1/ThiJ/Pfp I protein superfamily. DJ-1 is widely expressed in various tissues, and previous studies have shown that DJ-1 is associated with early-onset Parkinson's disease (6). Subsequent research has found that DJ-1 is associated with numerous types of cancer, such as lung and pancreatic cancer (7-9). DJ-1 promotes the active efflux of drugs and enhances the anti-apoptotic ability of multidrug resistant gastric cancer cells by upregulating P-gp and Bcl-2 (10). As an oncogene, DJ-1 was found to promote tumor cell migration and invasion through the PI3K/Akt/mTOR and SRC/ERK/uPA signaling pathways in pancreatic cancer (11,12). DJ-1 is suggested to promote the survival of human CRC cells through the PTEN-AKT, PLAGL2/Wnt/BMP4 or PI3K-AKT pathways (13-15).
addition, a number of studies have investigated treatment and diagnosis in clinical cancer. Overexpression of DJ-1 has been reported in numerous types of cancer, including breast cancer (9), melanoma (16), pancreatic cancer (17), astrocytic gliomas (18) and endometrial cancer (19). However, the precise role of DJ-1 in the occurrence and development, and clinical treatment of CRC remains unknown.

In the present study, DJ-1 was identified as a novel biomarker to predict the prognosis of patients with CRC. DJ-1 may predict the effect of chemotherapy based on clinical samples from CRC database, but further investigation is required to identify how DJ-1 regulates CRC cell proliferation, migration, invasion in vitro and in vivo.

Materials and methods

Patient specimens and tissue samples. The tissue microarray (TMA) cohort consisted of 470 CRC surgical samples from Yixing Hospital (Jiangsu, China) recruited between January 2000 to December 2006. These patients were followed up for at least 5 years. Overall survival (OS) was the primary endpoint of the analysis, and survival time was calculated from the date of surgery to the date of death or to the last follow-up. The median follow-up time was 59.3 months. In the CRC database, the mean age of all patients was 63 years. The age range was 30-88 years. There were 281 male and 189 female patients. The clinicopathological characteristics of the patients are summarized in Table SI.

A total of 8-paired fresh samples that were collected most recently were frozen in liquid nitrogen immediately for western blot analysis. The present study was granted ethical approval by the Institutional Review Board of Yixing Hospital Affiliated to Medical College of Yangzhou University (Yixing, Jiangsu). All patients provided written informed consent and all acquired data were assured of anonymity and confidentiality.

Construction of TMA. The CRC samples and matched non-cancerous colon tissues of patients with CRC were collected to construct the TMA. All tissue sections were fixed in formalin and embedded in paraffin. The CRC TMAs included 940 cores and were constructed by the Shanghai National Engineering Center for Biochip. Each sample was punched to a 1.0-mm diameter from the paraffin tumor block fixed in formalin and embedded in paraffin. The CRC TMAs subsequently performed and sample sections were sealed confidentially.

Immunohistochemistry (IHC). The standard protocol used for the immunostaining was used as previously described (20). The TMA was heated at 55˚C for 20 min and then washed with xylene containing 100 U/ml penicillin, 100 µg/ml streptomycin and 10% fetal bovine serum (FBS) and maintained at 37˚C in a humidified incubator with 5% CO₂.

Lentiviral infection and generation of stable cell lines. The HCT116 cells were infected with lentivirus (LV)-DJ-1, LV-DJ-1-control (ctrl), LV-DJ-1-RNA interference (RNAi) and LV-DJ-1-RNAi-ctrl with a multiplicity of infection (MOI) 20 and 10 µg/ml polybrene (Shanghai GeneChem Co., Ltd.). A total of 8 h after lentiviral infection, the HCT116 cells were maintained in RPMI-1640 medium. Subsequently after 24 h,
the cells were selected using puromycin (Gibco; Thermo Fisher Scientific, Inc.) at a final concentration of 2 µg/ml. The transgenic efficiency was detected using fluorescence microscopy according to the GFP of the lentivirus. The knockdown and overexpression efficiency of DJ-1 was further analyzed using western blot analysis.

**Cell Counting Kit (CCK)-8 assay.** The LV-DJ-1 and LV-DJ-1-RNAi HCT116 cells and the corresponding controls were seeded in 96-well plates at a density of 5x10^3 cells/100 µl culture medium per well in 96-well plates. The cell proliferation ability was analyzed 12, 24, 48, 60 and 72 h after cell culture using a CCK-8 solution (Dojindo Molecular Technologies, Inc.) according to the manufacturer's instructions. An automatic microplate reader measured the optical density of each well at 450 nm.

**EdU immunofluorescence assay.** The LV-DJ-1 and LV-DJ-1-RNAi HCT116 cells and the corresponding controls were seeded in 96-well plates at a density of 8x10^3 cells/100 µl culture medium. After 24 h of culture, EdU immunofluorescence analysis was performed using the EdU kit according to manufacturer's protocol (Guangzhou RiboBio Co., Ltd.).

**Cell cycle analysis.** The LV-DJ-1 and LV-DJ-1-RNAi HCT116 cells and the corresponding controls were seeded in 96-well plates at a density of 5x10^5 cells/100 µl serum-free RPMI-1640 medium. After 24 h of culture, EdU immunofluorescence analysis was performed using the EdU kit according to manufacturer's protocol (Guangzhou RiboBio Co., Ltd.).

**Transwell and Matrigel assays.** The LV-DJ-1 and LV-DJ-1-RNAi HCT116 cells and the corresponding controls were seeded with 70% cold ethanol overnight at 4°C and stained with 20 µg/ml propidium iodide (PI) in 0.1% Triton X-100 for 15 min. Samples were subsequently analyzed using a flow cytometer (BD Biosciences).

**Wound healing assay.** The LV-DJ-1 and LV-DJ-1-RNAi HCT116 cells and the corresponding controls were cultured in 6-well plates and grown to 80% confluence. The wound was scratched using a 10-µl pipette tip across the entire diameter of the well, and rinsed with PBS to remove all cellular debris. RPMI-1640 medium containing 2% FBS was then added to maintain cell growth during the assay. The process of tumor cell migration was observed and images were obtained at a low-power field (x40) under the 1X73 inverted fluorescence microscope at 0, 24 and 48 h after the wound was created. The closure rate reflected the migratory ability of the tumor cells. Three random measurements were made per photographed sample at every time point, which was used as baseline. AxioVision Rel. 4.8 software was used for the measurements.

**Western blot analysis.** Cells or tissues were lysed with cold lysis buffer supplemented with a protease inhibitor mixture on ice for 30 min. The total protein concentration was measured using the Bicinchoninic Acid Protein assay kit (Thermo Fisher Scientific, Inc.). Western blots were performed as previously described (23). The monoclonal mouse anti-DJ-1 (dilution 1:1,000; Santa Cruz Biotechnology, Inc.), monoclonal rabbit anti-cyclin E (dilution 1:1,000; Cell Signaling Technology, Inc.), anti-PI3K (dilution 1:1,000; Cell Signaling Technology, Inc.), anti-Akt (dilution 1:1,000; Cell Signaling Technology, Inc.), anti-p-PI3K (dilution 1:1,000; Cell Signaling Technology, Inc.), anti-Akt (dilution 1:1,000; Cell Signaling Technology, Inc.), anti-p-Akt (dilution 1:1,000; Cell Signaling Technology, Inc.) and anti-GFP (dilution 1:1,000; Cell Signaling Technology, Inc.) antibodies were used for antibody incubation overnight at 4°C. The polyclonal mouse anti-actin (dilution 1:2,000; cat. no. CSB-PA007670HA01; Wuhan Boster Biological Technology, Ltd.) was used for the protein loading control. Each blot was repeated three times. The intensity of the protein bands was analyzed using densitometry by Image J software (National Institutes of Health, Bethesda, MD, USA) after normalization to the corresponding protein controls.

**Reverse transcription-quantitative PCR (RT-qPCR).** The total RNAs from CRC and FHC cells were extracted using RNeasy Mini kit (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions using RNase-free conditions. The purified RNAs were reversely transcribed to first strand cDNA using a RevertAid RT reverse transcription kit (Thermo Fisher Scientific, Inc.). SYBR Green Real-Time qPCR analysis was performed using an Applied Biosystems 7500 Real-Time PCR System (Roche Applied Science). The thermocycling conditions are as follows: Pre-denaturation temperature: 95°C, 6 min; melting temperature: 95°C, 10 sec, 65°C, 60 sec, 97°C, 1 sec; amplification temperature: 95°C, 10 sec, 60°C, 10 sec, 72°C, 10 sec; then went through 40 cycles.

**Tumor xenograft and abdominal metastasis model.** In the tumor xenograft model, the LV-DJ-1 and LV-DJ-1-RNAi HCT116 cells and the corresponding controls (0.2 ml 1x10^7 cells/mouse; 5 mice/group) were injected subcutane-
WA NG et al.: DJ-1 PREDICTS PROGNOSIS AND CHEMOTHERAPY EFFICACY IN CRC

The tumor size was measured using a caliper upon palpable every 3 days. The following equation was used to calculate the tumor volume: \[ V = \frac{L \times W^2 \times \pi}{6} \] (V, volume; L, length; W, width). After 24 days, the mice were sacrificed by cervical dislocation. The tumors were removed and images were obtained. Each tumor was divided into 2 pieces and fixed in 10% buffered formalin.

In the peritoneal metastasis model, the same cells and groups were used as in the xenograft model, and inoculated into the peritoneal cavity of BALB/c nude mice. The weight of each mouse was recorded every 2 days. Mice were euthanized and examined macroscopically for the presence of peritoneal metastasis after 22 days. Intraperitoneal metastatic tumors were displayed, images were obtained and fixed in 10% formalin.

All experimental animal procedures were performed in compliance with the institutional ethics requirements and approved by the Institutional Animal Care and Use Committee of Yangzhou University.

Statistical analysis. The significance of associations between DJ-1 staining patterns and clinicopathological data was evaluated using Fisher's exact test. The paired Wilcoxon test (raw scores) was used to assess the significance of the difference of DJ-1 staining levels in tumor samples compared with that in the paired non-tumor samples. We used ANOVA (Tukey's) method to compare CRC cells with FHC cells, and the DJ-1 transfection groups with the control group. Kaplan-Meier survival analysis was performed to calculate OS and evaluate the prognostic value of patients with DJ-1 expression. Cox proportional hazards model was performed to analyze DJ-1 expression as a potential biomarker for predicting patient survival. All the statistical analyses were performed using STATA software (version 10.1; StataCorp LP). P<0.05 was considered to indicate a statistically significant difference.

Results

DJ-1 expression is increased in human CRC cells and tissues. The DJ-1 mRNA level was determined in human CRC and FHC cells using RT-qPCR. The DJ-1 mRNA level was significantly higher in the SW620, DLD-1, RKO, HCT116, SW480, HT29 and HCT15 cells compared with that in normal FHC cells (Fig. 1A). Simultaneously, DJ-1 protein expression was determined in six CRC cell lines and FHC using western blot analysis. The results revealed that DJ-1 protein expression was increased in the CRC cells compared with that in normal FHC cells (Fig. 1B). The expression of DJ-1 protein was further detected in 8 CRC tissues (C1-C8) and corresponding normal tissues (N1-N8). The expression of DJ-1 protein was increased in the CRC tissues compared with that noted in the paired normal colonic tissues (N1-N8) by western blot analysis. Densitometric analysis was presented as mean ± SD of 3 separate experiments (*P<0.05, **P<0.01). CRC, colorectal cancer.

Increased DJ-1 expression in CRC is associated with metastasis and poor OS in patients with CRC. To further reveal the role of DJ-1 in CRC, IHC was used to detect the expression of DJ-1 in a CRC TMA. Strong DJ-1 cytoplasm and nuclear staining was primarily found in CRC tissues and corresponding normal tissues (Fig. 2A). As shown in Fig. 2B, representative images of immunostaining revealed negative, weak, moderate, and strong expression levels in CRC tissues and corresponding normal tissues, and DJ-1 expression was upregulated in 351 of 451 (77.8%) tumors compared with that in the paired normal tissues (P<0.001; Fig. 2C).

In the CRC cohort, there was a significant association between high DJ-1 expression in cancerous tissues and depth of invasion (P<0.001), lymph node metastasis (P<0.001), and TNM stages (P<0.001; Table I). DJ-1 expression had a trend...
with age (P=0.050). There was no association between DJ-1 expression and sex, pathological classification, and tumor diameter (Table I). In addition, Kaplan-Meier survival curves were used to determine 5-year overall cumulative survival in patients with high and low DJ-1 expression levels. Patients with high DJ-1 expression levels had a worse OS compared with patients with low expression (P<0.001; Fig. 2E) and DJ-1 expression had the best predictive value for survival (Fig. 2D) upon assessment of IHC.

From the univariate and multivariate Cox regression analysis, DJ-1 expression was found to be an independent risk factor for the prognosis of CRC. The univariate Cox regression analysis revealed that age, pathological classification, depth of invasion, lymph node metastasis, TNM stage, distant metastasis and DJ-1 expression were associated with OS in patients with CRC (Table II). Subsequently, multivariate Cox regression analysis was used to verify the effect of DJ-1 expression, and the clinical parameters (sex, pathological classification, TNM stage and

Figure 2. DJ-1 is elevated in CRC and associated with poor prognosis of CRC patients. (A) Representative images of DJ-1 immunohistochemical staining in TMA are shown: Top panels, original magnification, x40; bottom panels, x200. (B) Representative images of DJ-1 immunohistochemical staining in CRC cancer and adjacent normal tissues. (a-d) Adjacent normal tissue and (e-h) cancer tissue. (a and e) Negative staining, (b and f) weak staining, (c and g) moderate staining and (d and h) strong staining. All panels, original magnification, x40. (C) Distribution of the difference in DJ-1 staining in CRC compared with that in the paired normal tissues in the TMA. The expression of DJ-1 was higher in cancer tissues than normal tissues (P<0.001). (D) Area under the curve (AUC) at different cut-off values for DJ-1 immunoreactivity score (IRS) for 1-, 3- and 5-year OS. The optimal cut-off point of DJ-1 IRS was 4. (E) Kaplan-Meier curves of the patients with low/high DJ-1 expression. CRC patients with high DJ-1 expression had a worse OS than the patients with low expression (P<0.001). CRC, colorectal cancer; TMA, tumor microarray; OS, overall survival.
Table I. Association between expression levels of DJ-1 and clinicopathological features in the CRC patients (N=460).

<table>
<thead>
<tr>
<th>Variables</th>
<th>DJ-1 expression</th>
<th></th>
<th>P-valuea</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Low, n (%)</td>
<td>High, n (%)</td>
<td></td>
</tr>
<tr>
<td>All patients</td>
<td>294 (63.9)</td>
<td>166 (36.1)</td>
<td>0.050</td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤65</td>
<td>177 (67.3)</td>
<td>86 (32.7)</td>
<td>0.229</td>
</tr>
<tr>
<td>&gt;65</td>
<td>117 (59.4)</td>
<td>80 (40.6)</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>180 (65.5)</td>
<td>95 (34.5)</td>
<td>0.454</td>
</tr>
<tr>
<td>Female</td>
<td>114 (61.6)</td>
<td>71 (38.4)</td>
<td></td>
</tr>
<tr>
<td>Pathological classificationb</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>3 (60.0)</td>
<td>2 (40.0)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>II</td>
<td>267 (64.3)</td>
<td>148 (35.7)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>III</td>
<td>19 (54.3)</td>
<td>16 (45.7)</td>
<td></td>
</tr>
<tr>
<td>Depth of invasionb</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1/T2</td>
<td>78 (78.8)</td>
<td>21 (21.2)</td>
<td></td>
</tr>
<tr>
<td>T3/T4</td>
<td>211 (59.3)</td>
<td>145 (40.7)</td>
<td></td>
</tr>
<tr>
<td>Lymph node metastasisb</td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>N0</td>
<td>204 (75.8)</td>
<td>65 (24.2)</td>
<td></td>
</tr>
<tr>
<td>N1/N2</td>
<td>86 (46.0)</td>
<td>101 (54.0)</td>
<td></td>
</tr>
<tr>
<td>TNM stageb</td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>I</td>
<td>68 (80.0)</td>
<td>17 (20.0)</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>133 (76.0)</td>
<td>42 (24.0)</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>82 (46.3)</td>
<td>95 (53.7)</td>
<td></td>
</tr>
<tr>
<td>IV</td>
<td>6 (35.3)</td>
<td>11 (64.7)</td>
<td></td>
</tr>
<tr>
<td>Tumor diameterb</td>
<td></td>
<td></td>
<td>0.529</td>
</tr>
<tr>
<td>≤5 cm</td>
<td>237 (63.9)</td>
<td>134 (36.1)</td>
<td></td>
</tr>
<tr>
<td>&gt;5 cm</td>
<td>56 (63.6)</td>
<td>32 (36.4)</td>
<td></td>
</tr>
<tr>
<td>Distant metastasis</td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>M0</td>
<td>288 (65.2)</td>
<td>154 (34.8)</td>
<td></td>
</tr>
<tr>
<td>M1</td>
<td>6 (33.3)</td>
<td>12 (66.7)</td>
<td></td>
</tr>
<tr>
<td>Adjuvant therapy</td>
<td></td>
<td></td>
<td>0.071</td>
</tr>
<tr>
<td>LFP regimen</td>
<td>60 (71.4)</td>
<td>24 (28.6)</td>
<td></td>
</tr>
<tr>
<td>Surgery alone</td>
<td>234 (66.7)</td>
<td>142 (33.3)</td>
<td></td>
</tr>
</tbody>
</table>

aTwo-sided Fisher’s exact tests. bFor some patients data concerning these clinical pathological parameters were not available. CRC, colorectal cancer; TNM, Tumor-Node-Metastasis; LFP, (regimen including oxaliplatin, 5-FU and tetrahydrofolate).

Lentivirus-mediated DJ-1 overexpression and knockdown in CRC cells. HCT116 cells transfected with either LV-DJ-1 or LV-DJ-1-RNAi exhibited increased or knocked down DJ-1 expression levels, respectively, compared with that in the respective control groups. As shown in Fig. 3A, the transfection efficiency with lentivirus and GFP was high. The lentivirus-mediated overexpression or knockdown of DJ-1 in HCT116 cells was subsequently analyzed using western blot analysis (Fig. 3B) and the results were consistent with fluorescence imaging.

Overexpression and knockdown of DJ-1 enhances and inhibits CRC cell proliferation. From the TMA data analysis, DJ-1 overexpression was associated with TNM stage in patients with CRC. It is unknown whether DJ-1 overexpression increases CRC cell growth. To investigate the biological role of DJ-1 in CRC cell proliferation, CCK-8 assay was used to observe the proliferation rate in DJ-1-overexpressing and -knockdown HCT116 cells and the corresponding control cells (Fig. 3C). Furthermore, the cell proliferation rate was investigated using EdU immunofluorescence assay (Fig. 3D). The results indicated that the cell proliferation ability was significantly increased after DJ-1 overexpression and significantly decreased when DJ-1 was knocked down in the HCT116 cells, when compared with that in the respective controls. To examine whether DJ-1 promoted CRC cell proliferation through directly acceleration of the progression of the cell cycle, cell cycle analysis was performed using PI and flow cytometry. As shown in Figs. 3E and SI, there was a significantly lower number of LV-DJ-1 cells in the G1 phase and a significantly higher number in the S phase, whereas significantly higher and lower numbers of LV-DJ-1-RNAi cells were observed in the G1 and S phase, respectively, compared with those of the corresponding control cells. The results indicate that DJ-1 promotes CRC cell proliferation and growth through regulation of the cell cycle.

Overexpression and knockdown of DJ-1 promotes and inhibits CRC cell migration and invasion, respectively. By analyzing the CRC database, DJ-1 expression was associated with lymph node metastasis in patients with CRC. To further clarify the role of DJ-1 in the metastasis of CRC, the migration and invasion abilities of LV-DJ-1, LV-DJ-1-ctrl, LV-DJ-1-RNAi and LV-DJ-1-RNAi-ctrl cell lines were observed using Transwell and wound healing, and Matrigel assays respectively. As shown in Fig. 4A, the results revealed that the migration and invasion abilities of LV-DJ-1 cells were increased, whereas the migration and invasion abilities of the LV-DJ-1-RNAi cells were decreased when compared with that in the corresponding controls, respectively. The mean number of migrated and invaded cells in the LV-DJ-1 group was 3.36- and 2.37-fold, respectively, whereas the number of migrated and invaded cells decreased by 68.0 and 23.5%, respectively, in the corresponding controls, respectively. These data further clarify the role of DJ-1 in the metastasis of CRC cell proliferation, migration and invasion, respectively.

Lentivirus-mediated DJ-1 overexpression and knockdown in CRCcells. HCT116 cells transfected with either LV-DJ-1 or LV-DJ-1-RNAi exhibited increased or knocked down DJ-1 expression levels, respectively, compared with that in the respective control groups. As shown in Fig. 3A, the transfection efficiency with lentivirus and GFP was high. The
protein levels. The data indicate that DJ-1 is able to activate the PI3K/Akt signaling pathway. The expression of PI3K/Akt downstream molecules, such as p27, cyclin E, mTOR, p-mTOR were also analyzed and the results revealed that DJ-1 negatively regulated p27 and cyclin E expression and positively regulated mTOR and p-mTOR expression (Fig. 4D and E). These results from the present study suggest that DJ-1 regulates the PI3K/AKT/p27/cyclin E and PI3K/Akt/mTOR signaling pathways to promote CRC cell growth and metastasis.

**DJ-1 induces CRC cell EMT to promote migration and invasion.** Previous studies have demonstrated that DJ-1 is upregulated in renal fibrosis and DJ-1 mediates EMT by suppressing cytoplasmic PTEN expression and Akt activation (25). Epithelial marker (E-cadherin) and mesenchymal markers (N-cadherin and vimentin) are markers for the occurrence of EMT. We investigated whether DJ-1 stimulates CRC cells to induce EMT, which consequently promotes CRC cell invasion and metastasis. The results from western blot analysis revealed that protein expression level of E-cadherin was reduced following DJ-1 overexpression, whereas E-cadherin was upregulated following knockdown of DJ-1, when compared with the corresponding controls, respectively. The expression of N-cadherin and vimentin was inversely associated with DJ-1 expression. The data confirmed that DJ-1 regulates the PI3K/Akt/p27/cyclin E and PI3K/Akt/mTOR signaling pathways to promote CRC cell growth and metastasis.

**DJ-1 increases CRC cell growth and induces CRC cell metastasis in vivo.** LV-DJ-1, LV-DJ-1-ctrl, LV-DJ-1-RNAi and LV-DJ-1-RNAi-ctrl cell lines exhibited differential levels of DJ-1 (Fig. 5A). These four groups cells were injected subcutaneously into nude mice, and tumor growth was monitored (Fig. 5B). Tumor volume was increased in the LV-DJ-1 group, whereas it was decreased in LV-DJ-1-RNAi group when compared with that in the respective control groups (Fig. 5B and C). Furthermore, the protein expression levels of DJ-1, p-PI3K, p-Akt, p27 and cyclin E in the xenograft tumors were determined using IHC. The results revealed that DJ-1 expression in tumors was higher in the LV-DJ-1 group and lower in the LV-DJ-1-RNAi group compared with that in the respective control groups. The DJ-1 expression was positively associated with the expression of p-PI3K, p-Akt and cyclin E, whereas it was negatively associated with p27 expression (Fig. 5D and E). In addition, the aforementioned transfected cells were inoculated into the peritoneal cavity of BALB/c nude mice. The weight of each mouse was monitored every 2 days. The relative weight of the mice in the LV-DJ-1 group was significantly reduced at days 18, 20 and 22 compared with that in the control group, whereas the weight of the mice in the LV-DJ-1-RNAi group increased at days 16, 18, 20 and 22 compared with that in the control group (Fig. 6A). These mice were sacrificed by cervical dislocation on day 22, and the number of metastatic nodules was higher in the LV-DJ-1-RNAi group increased at days 16, 18, 20 and 22 compared with that in the control group (Fig. 6A). These mice were sacrificed by cervical dislocation on day 22, and the number of metastatic nodules was higher in the LV-DJ-1-RNAi group, whereas it was decreased in LV-DJ-1-RNAi group compared with that in the respective control groups (Fig. 5B and C). Furthermore, the protein expression levels of DJ-1, p-PI3K, p-Akt, p27 and cyclin E in the xenograft tumors were determined using IHC. The results indicated...
that DJ-1 expression was positively associated with the expression levels of p-PI3K, p-Akt and p-mTOR (Fig. 6C and D). Furthermore, the expression levels of EMT-related proteins (NF-κB, Snail, E-cadherin, N-cadherin and vimentin) were also determined in intraperitoneal metastasis. The expression levels of NF-κB, Snail, N-cadherin and vimentin were positively regulated by the expression of DJ-1, whereas E-cadherin was negatively associated with DJ-1 expression (Fig. 6E and F).

The data from the present study revealed that DJ-1 was also capable of promoting CRC cell growth and metastasis in vivo, which is consistent with the results from CRC cell proliferation and invasion in vitro.

Patients with low DJ-1 expression levels are more sensitive to adjuvant chemotherapy. In the CRC database, the postoperative chemotherapy of each patient with CRC was recorded in detail. According to the National Comprehensive Cancer Network guidelines at that time, the recommended first-line postoperative adjuvant chemotherapy for patients with CRC is the LFP regimen, which includes oxaliplatin, 5-FU and tetrahydrofolate (26). Subsequently, the correlation between DJ-1 expression and the therapeutic effect of chemotherapy was investigated. Kaplan-Meier curve analysis revealed that patients who received LFP treatment and had low DJ-1 expression levels in tumor tissues had a significantly longer survival time compared with that in patients who received surgery alone (Fig. 7A; P=0.011). However, patients with high DJ-1 expression level did not benefit from LFP treatment (Fig. 7B; P=0.191). Multivariate Cox proportional hazard regression analysis, including 6 variables (age, sex, TNM stage, pathological classification, tumor diameter and adjuvant chemotherapy), was used to evaluate the benefit of chemotherapy on OS. Notably, LFP treatment increased OS compared with that with surgery alone in patients with low DJ-1 expression levels (HR,
Figure 4. DJ-1 positively regulates CRC cell migration and invasion in vitro. (A and B) The cell migration and invasion results of HCT116 cells with different DJ-1 expression levels. Numbers of cell migration and invasion per field were counted in five random fields for the DJ-1-overexpressing/knockout and control groups (n=3/group). The ability of cell migration and invasion was increased after DJ-1 over-expression, whereas the ability of cell migration and invasion was decreased after DJ-1 knockout (**P<0.01). (C) Wound healing assay was used to detect the migratory ability of HCT116 cells with differential DJ-1 expression levels. The wound healing rate of LV-DJ-1 cells was higher than that of the LV-DJ-1-ctrl cells, whereas the wound healing rate was lower in the LV-DJ-1-RNAi cells compared with the control groups. (D and E) The expression of PI3K/Akt downstream molecules such as p27, cyclin E, mTOR, p-mTOR was detected by western blot analysis. (F and G) Nuclear transcription factors (NF-κB, Snail), EMT markers (E-cadherin, N-cadherin, and vimentin) were evaluated by western blot analysis. DJ-1 was able to regulate the NF-κB/Snail signaling pathway to induce EMT. CRC, colorectal cancer; EMT, epithelial-mesenchymal transition. The HCT116 cells were infected with lentivirus (LV)-DJ-1, LV-DJ-1-ctrl, LV-DJ-1-RNA interference (RNAi) and LV-DJ-1-RNAi-ctrl.
However, this effect was not observed in patients with high DJ-1 expression levels (HR, 0.634; 95% CI, 0.355-1.32; P=0.124; Table III).

In addition, the association between DJ-1 expression and chemosensitivity was investigated in vitro. A drug which contains 5-FU (25 µg/ml) and L-OHP (20 µg/ml) was used to act on LV-DJ-1, LV-DJ-1-ctrl, LV-DJ-1-RNAi and LV-DJ-1-RNAi-ctrl cell lines. As in Fig. 7C, DJ-1 expression in these four groups was again verified by Western blot analysis. The inhibition rate was determined using CCK-8 assay. The results indicate that the inhibition rate in the LV‑DJ‑1‑RNAi group was significantly higher when compared with that in LV-DJ-1-RNAi-ctrl group (P<0.01; Fig. 7D); however, the inhibition rate in the LV-DJ-1 group was not statistically significant compared with that in the control group (P>0.05; Fig. 7D). These results suggest that DJ-1 expression may predict the effect of LFP chemotherapy in patients with CRC.

Discussion

The pathogenesis of colorectal cancer (CRC) is a complex process, which is associated with the abnormal expression of oncogenes and tumor-suppressor genes (27). In the progression of CRC, novel molecular markers may be valuable as early diagnostic markers or indicators of treatment efficacy (28). Our previous research revealed that molecular markers can predict metastasis and prognosis in patients with CRC (29,30). In the present study, protein/nucleic acid deglycase DJ-1 (DJ-1) expression was found to be significantly different between
CRC and FHC cell lines, and between CRC tissues and normal adjacent tissues. Furthermore, subsequent experiments were performed to fully elucidate the underlying mechanisms and clinical significance of DJ-1 in CRC.

DJ-1 is associated with the development of cancer. Previous studies have revealed that DJ-1 promoted the invasion and metastasis in numerous types of tumors, including liver cancer (31), laryngeal carcinoma (32), lung cancer (33), and breast cancer (33). The mechanism involved may be associated with PI3K/Akt, SRC/ERK/uPA and other signaling pathways (12,25,34). Additionally, DJ-1 could induce apoptosis and promote cell EMT (25,35). In the present study, patients with CRC and high DJ-1 expression levels had a poorer disease-free survival, and multivariate Cox proportional hazards regression analysis revealed that DJ-1 expression was an independent negative prognostic factor following adjustment by sex, pathological classification, TNM stage and tumor diameter in CRC database analysis.

To validate these results, LV-DJ-1, LV-DJ-1-ctrl, LV-DJ-1-RNAi and LV-DJ-1-RNAi-ctrl cell lines were constructed to investigate the biological function of DJ-1 in CRC. In vitro, cell proliferation was significantly increased in
LV-DJ-1 and decreased in LV-DJ-1-RNAi cells when compared with that in the respective controls. Moreover, the migration and invasion abilities of the LV-DJ-1 cells were increased, whereas these abilities were decreased in the LV-DJ-1-RNAi cells when compared with those in the corresponding controls. Previous research mechanisms have been clarified that DJ-1 could promote CRC cell growth or metastasis through the PTEN-AKT, PLAGL2/Wnt/BMP4 pathways (13,14). Subsequently, the related mechanisms involved were investigated in the present study. The results indicated that increased DJ-1 expression induced cell proliferation by regulating PI3K/Akt/p27/cyclin E signaling, and promoted cell invasion and metastasis by regulating PI3K/Akt/mTOR signaling or induced EMT in vitro.

In addition, two models of subcutaneous implantation and
peritoneal metastases were constructed to investigate the role of DJ-1 in tumorigenesis. The growth of tumors was observed and the regulation between DJ-1 and p-Pi3K, p-Akt, p27 and cyclin E protein expression in xenograft tumor tissues was validated using IHC. In addition, the expression levels of DJ-1, p-Pi3K, p-Akt, p-mTOR, NF-κB, Snail, E-cadherin, N-cadherin and vimentin were also analyzed in peritoneal metastasis tumor tissues. The analysis of these results indicates that DJ-1 promotes CRC cell growth and metastasis in vivo, which is consistent with the results from CRC cell proliferation and invasion in vitro.

Notably, the CRC database, which contains samples from 470 patients, was used to investigate the association between DJ expression and postoperative adjuvant chemotherapy. In the CRC database, 86 patients with CRC were treated with LFP chemotherapy. Using the Kaplan-Meier curve method and multivariate Cox proportional hazard regression, LFP treatment increased the overall survival (OS) compared with that in patients who underwent surgery alone and with low DJ-1 expression levels, whereas a lower OS was found in patients with high DJ-1 expression levels. To confirm this conclusion, the drugs 5-FU and L-OHP were used to act on LV-DJ-1, LV-DJ-1-ctrl, LV-DJ-1-RNAi and LV-DJ-1-RNAi-ctrl cell lines. The results indicate that the inhibition rate of the LV-DJ-1-RNAi group was higher compared with that in the LV-DJ-1-RNAi-ctrl group, but not in the LV-DJ-1 group.

In conclusion, DJ-1 was the most unfavorable prognostic factor for patients with CRC. High DJ-1 expression levels are positively associated with poorer survival in patients with CRC. The investigations into the molecular mechanisms revealed that DJ-1 increased cell proliferation by regulating the Pi3K/Akt/p27/cyclin E signaling pathway and induced CRC metastasis via regulating the Pi3K/Akt/mTOR signaling pathway or by inducing EMT in vitro and in vivo. DJ-1 may play a role as an oncogene in CRC tumorigenesis and may be involved in the progression of CRC. Therefore, DJ-1 appears to be a significant prognostic indicator for patients with CRC and an effective marker for predicting the efficacy of chemotherapy. However, the results from the present study require validation in larger retrospective and prospective CRC cohorts.

Acknowledgements

Not applicable.

Funding

The present study was supported by the National Natural Science Foundation of China (grant no. 81773944), the Young Medicine Focus Talent Foundation of Jiangsu Province (grant no. QNRC2016206), the Postgraduate Research by Practice Innovation Program of Jiangsu Province (grant nos. KYCX18_2382 and KYCX17_1892), the Wuxi City Health Planning Commission project (grant no. MS201815), and the Natural Science Foundation of Jiangsu Province of China (grant no. BK20191149).

Availability of data and materials

The datasets used during the present study are available from the corresponding author upon reasonable request.

Authors’ contributions

YuZ and YL conceived and coordinated the project. WW, HW, LX, TN and FJ performed experiments and collected the data. WW and LX performed overall data interpretation. JD, YuZ, and IS interpreted the data and critically reviewed the manuscript. WW wrote the manuscript. All authors read and approved the manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate

The present study was granted ethics approval by the Institutional Review Board of Yixing Hospital Affiliated to Medical College of Yangzhou University (Yixing, Jiangsu). All patients provided written informed consent and all acquired data were assured of anonymity and confidentiality. All experimental animal procedures were performed in compliance with the institutional ethics requirements and approved by the Institutional Animal Care and Use Committee of Yangzhou University.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


